Liquid Biopsy and Cancer Screening Tests for Dogs: Promise, Limits, and Responsible Use
Summary
A 2026 evidence-boundary review explaining why emerging blood or urine cancer tests may add information but cannot currently replace examination, imaging, or tissue diagnosis.
Article
Current-evidence review. Blood and urine tests marketed for canine cancer screening or detection are often described as liquid biopsies, multicancer detection tests, or biomarker panels. The idea is appealing: identify tumor-related material with a convenient sample. The 2026 AAHA oncology guidelines, however, state that no current blood or urine test can conclusively rule cancer in or rule it out in a veterinary patient. These tools may contribute information in selected settings, but they are not substitutes for clinical diagnosis.
Screening, detection, diagnosis, and monitoring differ
Screening tests an animal without a specific cancer sign. Detection suggests that a cancer-related signal may be present. Diagnosis establishes what disease exists, usually through cytology or histopathology integrated with clinical findings. Monitoring follows a known condition or treatment response. A test validated for one purpose should not automatically be used for another.
Why test performance depends on context
Sensitivity describes how often a test detects the target condition when it is present; specificity describes how often it is negative when the condition is absent. Neither number tells an owner the chance that this dog's result is correct without considering pretest probability—the likelihood of disease before testing. In a low-risk screening population, even a highly specific test can generate false-positive results. In early, small, or biologically quiet tumors, a test can be falsely negative because the detectable signal is limited.
Performance can also vary by tumor type, stage, sample handling, and the threshold chosen. A single overall accuracy figure may hide strong detection for some cancers and weak detection for others.
What a positive result does not tell you
A positive signal may increase concern but may not identify the exact tissue, anatomical site, grade, stage, or best treatment. The next step usually requires a veterinarian to integrate history, physical examination, targeted imaging, and cell or tissue sampling. Testing without a predefined follow-up plan can create anxiety, cost, and invasive procedures without a clear benefit.
What a negative result cannot promise
A negative result is not permission to ignore a growing mass, unexplained bleeding, persistent lameness, weight loss, or another concerning sign. When a lesion is accessible, microscopic sampling remains central because a local tumor can be present even when a circulating marker is not detected. AAHA further notes that evidence is currently insufficient to conclude that emerging liquid-biopsy approaches meaningfully improve animal outcomes.
Questions before purchasing a test
- Is the test intended for screening, detection, diagnosis support, or monitoring?
- In what dog population and tumor types was it validated?
- What are sensitivity and specificity by cancer type and stage?
- Was performance confirmed independently and prospectively?
- What will we do after a positive, negative, or indeterminate result?
- Could the result change a decision we are prepared to make?
- Does the laboratory provide veterinary consultation and transparent limitations?
A responsible place in the pathway
An emerging test may be reasonable when a veterinarian believes it can refine a defined question and when confirmatory care is available. It should be interpreted alongside—not instead of—the examination, conventional laboratory data, imaging, and pathology. Owners should be told what remains unknown and should not be offered certainty that the evidence cannot support.
Research outlook
These technologies are developing quickly, and future studies may establish value for specific populations, tumor types, or monitoring tasks. Useful research must show more than analytical detection: it should demonstrate that testing leads to earlier actionable diagnosis, better quality of life, or improved outcomes without disproportionate harm from false results. Recommendations should be revisited as independent evidence evolves.
Medical disclaimer: This article is educational and does not recommend or interpret any commercial cancer test. A blood or urine result cannot diagnose or exclude cancer for an individual dog. Discuss signs, risk, and confirmatory options with a licensed veterinarian; do not delay examination or biopsy of a concerning lesion because of a screening result.